SDIC Securities released a research report on April 16 stating that Rongtai Health (603579.SH) was given a purchase rating and the target price was 28.62 yuan. The main reasons for the rating include: 1) revenue growth in Q4 was corrected; 2) Q4 profitability increased year-on-year; 3) Q4 operating cash flow improved markedly year-on-year. (Mainichi Keizai Shimbun)
国投证券4月16日发布研报称，给予荣泰健康（603579.SH）买入评级，目标价格为28.62元。评级理由主要包括：1）Q4单季收入增速转正；2）Q4盈利能力同比提升；3）Q4单季经营性现金流同比明显改善。（每日经济新闻）
SDIC Securities released a research report on April 16 stating that Rongtai Health (603579.SH) was given a purchase rating and the target price was 28.62 yuan. The main reasons for the rating include: 1) revenue growth in Q4 was corrected; 2) Q4 profitabi
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.